Matthias Kant

1.2k total citations
23 papers, 455 citations indexed

About

Matthias Kant is a scholar working on Pathology and Forensic Medicine, Neurology and Hematology. According to data from OpenAlex, Matthias Kant has authored 23 papers receiving a total of 455 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Pathology and Forensic Medicine, 9 papers in Neurology and 4 papers in Hematology. Recurrent topics in Matthias Kant's work include Multiple Sclerosis Research Studies (19 papers), Peripheral Neuropathies and Disorders (7 papers) and Autoimmune and Inflammatory Disorders Research (4 papers). Matthias Kant is often cited by papers focused on Multiple Sclerosis Research Studies (19 papers), Peripheral Neuropathies and Disorders (7 papers) and Autoimmune and Inflammatory Disorders Research (4 papers). Matthias Kant collaborates with scholars based in Denmark, Norway and Sweden. Matthias Kant's co-authors include Melinda Magyari, Finn Sellebjerg, Peter Vestergaard Rasmussen, Hanna Joensen, Anders Svenningsson, Tim Spelman, Fredrik Piehl, Jan Lycke, Jan Hillert and S. Fredrikson and has published in prestigious journals such as PLoS ONE, Neurology and JAMA Neurology.

In The Last Decade

Matthias Kant

20 papers receiving 446 citations

Peers

Countries citing papers authored by Matthias Kant

Since Specialization

Citations

This map shows the geographic impact of Matthias Kant's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthias Kant with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthias Kant more than expected).

Fields of papers citing papers by Matthias Kant

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthias Kant. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthias Kant. The network helps show where Matthias Kant may publish in the future.

Co-authorship network of co-authors of Matthias Kant

This figure shows the co-authorship network connecting the top 25 collaborators of Matthias Kant. A scholar is included among the top collaborators of Matthias Kant based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthias Kant. Matthias Kant is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Patterns and predictors of multiple sclerosis phenotype transition 2024 ·Brain Communications ·Luigi Pontieri, (unknown), (unknown), Svend Sparre Geertsen, Nasrin Asgari, Henrik Boye Jensen, Zsolt Illés, (unknown), (unknown), Tobias Sejbæk, (unknown), (unknown), (unknown), (unknown), Morten Stilund, Matthias Kant, Peter Vestergaard Rasmussen, Kristina Bacher Svendsen, Finn Sellebjerg, Melinda Magyari	2
2	Effect of alemtuzumab on fatigue, quality of life, and patient/caregiver-reported outcomes in relapsing-remitting multiple sclerosis—A real-world evidence study 2024 ·Multiple Sclerosis and Related Disorders ·Jette Lautrup Frederiksen, Luca Massacesi, Helle Hvilsted Nielsen, Augusto Rini, Eleonora Baldi, Massimiliano Mirabella, (unknown), Giacomo Lus, Damiano Paolicelli, Matthias Kant, Giuseppe Salemi, Umberto Aguglia, Cristoforo Comi, Milena De Riz, Valeria Barcella, Heidi Øyen Flemmen, Alessandra Protti, (unknown), Job van Exel, Øivind Torkildsen	0
3	Discontinuation of dimethyl fumarate in multiple sclerosis - a nationwide study 2023 ·Multiple Sclerosis and Related Disorders ·(unknown), (unknown), (unknown), (unknown), Morten Stilund, (unknown), Rikke Ratzer, Jette Lautrup Frederiksen, Nasrin Asgari, (unknown), Henrik Boye Jensen, Matthias Kant, (unknown), Zsolt Illés, Finn Sellebjerg, Melinda Magyari, (unknown), (unknown), Stig Wergeland, Tobias Sejbæk	1
4	Natalizumab treatment of multiple sclerosis — a Danish nationwide study with 13 years of follow-up 2023 ·Multiple Sclerosis and Related Disorders ·Mathias Due Buron, Jeppe Romme Christensen, Luigi Pontieri, Hanna Joensen, Matthias Kant, Peter Vestergaard Rasmussen, Finn Sellebjerg, Per Soelberg Sørensen, (unknown), Melinda Magyari	3
5	Cannabis-Based Medicine for Neuropathic Pain and Spasticity—A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial 2023 ·Pharmaceuticals ·(unknown), (unknown), Stefan Gustavsen, Homayoun Roshanisefat, Matthias Kant, Fin Biering‐Sørensen, Claus Yding Andersen, Anna Olsson, (unknown), Nasrin Asgari, (unknown), (unknown), Helle Hvilsted Nielsen, Rikke Middelhede Hansen, Thor Petersen, Annette Oturai, Finn Sellebjerg, Eva Aggerholm Sædder, Helge Kasch, Peter Vestergaard Rasmussen, Nanna Brix Finnerup, Kristina Bacher Svendsen	14
6	Risk factors for development of lymphopenia in dimethyl fumarate-treated patients with multiple sclerosis 2022 ·Multiple Sclerosis and Related Disorders ·J. J. RAVN, Henrik Boye Jensen, Matthias Kant, (unknown), (unknown), Tobias Sejbæk	7
7	Real-world study of relapsing-remitting multiple sclerosis patients treated with Teriflunomide in Nordic countries: Quality-Of-Life, efficacy, safety and adherence outcomes 2022 ·Multiple Sclerosis and Related Disorders ·(unknown), Jette Lautrup Frederiksen, Helle Hvilsted Nielsen, Øivind Torkildsen, (unknown), Yu-Min Huang, Sara Haghighi, Jon A. Tsai, Matthias Kant	3
8	Investigating the potential disease-modifying and neuroprotective efficacy of exercise therapy early in the disease course of multiple sclerosis: The Early Multiple Sclerosis Exercise Study (EMSES) 2022 ·Multiple Sclerosis Journal ·Morten Riemenschneider, Lars G. Hvid, Steffen Ringgaard, (unknown), Simon Fristed Eskildsen, (unknown), Melinda Magyari, Henrik Boye Jensen, Helle Hvilsted Nielsen, Matthias Kant, (unknown), Thor Petersen, Egon Stenager, Ulrik Dalgas	33
9	Alemtuzumab treatment in Denmark: A national study based on the Danish Multiple Sclerosis Registry 2021 ·Multiple Sclerosis Journal ·(unknown), Birgit Debrabant, Melinda Magyari, Matthias Kant, Peter Vestergaard Rasmussen, (unknown), (unknown), (unknown), (unknown), (unknown), Karen Schreiber, Jette Lautrup Frederiksen, Finn Sellebjerg, Zsolt Illés	15
10	Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis Registry 2021 ·PLoS ONE ·Viktoria Papp, Mathias Due Buron, Volkert Siersma, Peter Vestergaard Rasmussen, Zsolt Illés, Matthias Kant, (unknown), J. Zs. Mezei, Homayoun Roshanisefat, Tobias Sejbæk, (unknown), (unknown), Svend Sparre Geertsen, Stephan Bramow, Finn Sellebjerg, Melinda Magyari	11
11	Application of definitions for conversion to secondary progressive MS in a Danish nationwide population 2021 ·Multiple Sclerosis and Related Disorders ·Tine Iskov Kopp, Stephan Bramow, Zsolt Illés, Matthias Kant, (unknown), Peter Vestergaard Rasmussen, Finn Sellebjerg, Melinda Magyari	6
12	Ocrelizumab treatment in multiple sclerosis: A Danish population‐based cohort study 2021 ·European Journal of Neurology ·Luigi Pontieri, Morten Blinkenberg, Stephan Bramow, Viktoria Papp, Peter Vestergaard Rasmussen, Matthias Kant, (unknown), (unknown), Michael Broksgaard Jensen, (unknown), (unknown), Tine Iskov Kopp, Hanna Joensen, Finn Sellebjerg, Melinda Magyari	18
13	Early experience with ocrelizumab in denmark. A population-based registry study 2020 ·Multiple Sclerosis Journal ·Melinda Magyari, Luigi Pontieri, Morten Blinkenberg, Viktoria Papp, Peter Vestergaard Rasmussen, (unknown), (unknown), Matthias Kant, (unknown), Michael Broksgaard Jensen, (unknown), Anders Petersen, Stephan Bramow, Finn Sellebjerg	1
14	Initial high-efficacy disease-modifying therapy in multiple sclerosis 2020 ·Neurology ·Mathias Due Buron, (unknown), Finn Sellebjerg, (unknown), (unknown), Jeppe Romme Christensen, (unknown), (unknown), Zsolt Illés, Henrik Boye Jensen, Matthias Kant, Viktoria Papp, Thor Petersen, (unknown), Peter Vestergaard Rasmussen, (unknown), (unknown), (unknown), Per Soelberg Sørensen, Melinda Magyari	107
15	Comparative effectiveness of teriflunomide and dimethyl fumarate 2019 ·Neurology ·Mathias Due Buron, (unknown), Finn Sellebjerg, Jette Lautrup Frederiksen, (unknown), Zsolt Illés, Matthias Kant, J. Zs. Mezei, Thor Petersen, Peter Vestergaard Rasmussen, Homayoun Roshanisefat, (unknown), Tobias Sejbæk, (unknown), (unknown), Per Soelberg Sørensen, Melinda Magyari	29
16	High treatment adherence, satisfaction, motivation, and health-related quality of life with fingolimod in patients with relapsing-remitting multiple sclerosis – results from a 24-month, multicenter, open-label Danish study 2018 ·Patient Preference and Adherence ·(unknown), Matthias Kant, Claudia Pfleger, Henrik Boye Jensen, (unknown), (unknown), (unknown), Sune Rubak	6
17	Differences between users and non-users of complementary and alternative medicine among people with multiple sclerosis in Denmark: A comparison of descriptive characteristics 2013 ·Scandinavian Journal of Public Health ·Lasse Skovgaard, (unknown), (unknown), Matthias Kant, S. Fredrikson, Marja J. Verhoef, Dan Wolf Meyrowitsch	24
18	People with multiple sclerosis in Denmark who use complementary and alternative medicine—Do subgroups of patients differ? 2013 ·European Journal of Integrative Medicine ·Lasse Skovgaard, (unknown), Elisabeth Pedersen, Matthias Kant, S. Fredrikson, Marja J. Verhoef, Dan Wolf Meyrowitsch	3
19	Krafttraining bei schubförmig verlaufender Multipler Sklerose 2010 ·Aktuelle Neurologie ·Ulrik Dalgas, Matthias Kant, Egon Stenager	0
20	Incidence of anisometropic amblyopia in Zambia. 1983 ·PubMed ·Matthias Kant	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact